ASAH1 Antibody
| Code | Size | Price |
|---|
| PSI-4741-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4741-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
ASAH1 Antibody: AC, PHP, ASAH, PHP32, ACDase, SMAPME, HSD-33, HSD33, Acid ceramidase, Acylsphingosine deacylase, AC
Application Note:
ASAH1 antibody can be used for detection of ASAH1 by Western blot at 1 and 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human and rat samples and Immunofluorescence in human and rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human and rat samples and Immunofluorescence in human and rat samples. All other applications and species not yet tested.
Background:
ASAH1 Antibody: Sphingolipids are hydrolyzed by ceramidases to yield sphingosine and fatty acids. These ceramidases are classified according to the pH range that supports their optimal activity. ASAH1 is an acid ceramidase and key regulator of ceramide metabolism. Mutations in this gene results in Farber Lipogranulomatosis, a fatal human genetic disorder that results in the painful swelling of the joints and tendons and pulminary insufficiency, while a complete knockout of its expression is lethal in mice. Recent studies have shown elevated levels of ASAH1 in Alzheimer's disease (AD) patients correlating with a reduction in sphingomyelin and elevation of ceramide. Pretreatment of cultured neurons with recombinant AHAH1 prevented the cells from undergoing A-beta (Ab)-induced apoptosis.
Background References:
- Nilsson A and Duan RD. Alkaline sphingomyelinases and ceramidases of the gastrointestinal tract. Chem. Phys. Lipids 1999; 102:97-105.
- Koch J, Gartner S, Li CM, et al. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing Farber's disease. J. Biol. Chem. 1996; 271:33110-5.
- Li CM, Park JH, Simonaro CM, et al. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics 2002; 79:218-24.
- He X, Huang Y, Li B, et al. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol. Aging 2010; 31:398-408.
Buffer:
ASAH1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (88%)
Immunogen:
ASAH1 antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of the human ASAH1.
The immunogen is located within amino acids 240 - 290 of ASAH1.
The immunogen is located within amino acids 240 - 290 of ASAH1.
NCBI Gene ID #:
427
NCBI Official Name:
N-acylsphingosine amidohydrolase (acid ceramidase) 1
NCBI Official Symbol:
ASAH1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 45 kDa
Observed: 49 kDa
Observed: 49 kDa
Protein Accession #:
EAW63795
Protein GI Number:
119584199
Purification:
ASAH1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
SPECIFICITY:
Multiple isoforms of ASAH1 are known to exist.
Swissprot #:
Q13510
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | ASAH1 Peptide | PSI-4741P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|